Acute Respiratory Tract InfectionPOS-ARI-PCNCT06282718
A Long-term Observational Study Evaluating the Presentation and Management of Acute Respiratory Tract Infections in Primary Care Across Europe
An observational study of Acute Respiratory Tract Infection, run by European Clinical Research Alliance for Infectious Diseases (ECRAID) at 3 sites in 3 countries.
Trial summary
Acute respiratory infection (ARI) is the commonest reason for consulting in community care. Furthermore, new and re-emerging pathogens are often first noticed in primary care (PC). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Acute Respiratory Tract Infection
- Type of treatment
- Vaccines
- How many people
- 2,000 participants
- Where
- 3 sitesin 3 countries
- Study dates
- 22 Feb 2024to 30 Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients of any age group presenting to primary care settings with an ARI.
Who may be able to join
- Eligible patients will be of any age consulting (telephone, video, face-to-face) with a participating health care facility with:
- Symptoms suggestive of an acute lower RTI with cough as predominant symptom and with illness duration less than 28 days, AND/OR
- Symptoms suggestive of an acute upper RTI with sore throat and/or coryza as predominant symptom and with illness duration of less than 14 days AND/OR
- Patients otherwise suspected of COVID-19, influenza or RSV.
- Eligible patients will be of any age consulting (telephone, video, face to face) with a participating primary health care facility with:
- Symptoms suggestive of an acute lower respiratory infection with cough as the predominant symptom, with illness duration less than 28 days, AND/OR
Show all 9Show fewer
- Symptoms suggestive of an acute upper respiratory infection with sore throat and/or coryza as the predominant symptom, with illness duration of less than 14 days AND/OR
- Other symptoms suggestive of COVID-19, Influenza, RSV AND
- Participant or legal guardian(s) willing and able to provide informed consent and comply with study procedures
Who cannot join
- Patients will not be eligible for if they have withdrawn their consent for anonymous data collection for research by their health care facility.
- POS-ARI-PC CORE:
- Patients will not be eligible if:
- According to the judgement of the recruiting clinician, they will not be able comply with study procedures, for example because they do not understand the language in which the study is being conducted locally (and have no one to help and translate for them); have a serious psychiatric disorder; or are terminally ill
- Symptoms of presumed non-infective origin
- Participant requires admission to hospital on the day of inclusion
Show all 12Show fewer
- Additional in/exclusion criteria might apply to embedded studies and will be described in the SSA or ISA.
- POS-ARI-PC-001:
- Symptoms and Duration Symptoms suggestive of an acute lower RTI with new or increased cough as the predominant symptom, with illness duration ≤10 days; AND/OR Symptoms suggestive of an acute upper RTI with sore throat and/or coryza as the predominant symptom, with illness duration ≤10 days;
- Age Aged 60 years and over OR Aged 50 to 59 years and have a long-term health condition which makes them eligible for the yearly influenza vaccination under the national influenza vaccination programme;
- Consent Willing and able to provide informed consent and have a swab taken.
- As per the POS-ARI-PC CORE Protocol, with one exception: patients needing hospitalisation can be recruited into the study if timing allows. Patients can provide a swab and decide not to participate in the follow-up procedures.
Trial locations and contacts
3 sites in 3 countries. Contact the study team or a site near you to ask about taking part.
Nguyen Tran contact
3 sites in 3 countries
Belgium1 site, 1 recruiting
- Recruiting
Universiteit Antwerpen
Antwerp
Stefan Morreel, PhD
France1 site, 1 recruiting
- Recruiting
Centre Hospitalier Universitaire de Limoges
Limoges
Elodie Pfender
United Kingdom1 site, 1 recruiting
- Recruiting
University of Oxford
Oxford
Nguyen Tran, PhD
About this study
Official title: Perpetual Observational Study (POS) of Acute Respiratory Infections (ARI) in Primary Care Settings (PC) Across Europe
Acute respiratory infection (ARI) is the commonest reason for consulting in community care. Furthermore, new and re-emerging pathogens are often first noticed in primary care (PC). The POS-ARI-PC study is a long-term study, with the aim of describing the nature of ARI in adults and children presenting to PC across Europe. The POS-ARI-PC study will provide critically important data on the presentation and management of ARI, and build a research-ready infrastructure for studies related to the treatment, diagnosis, and prevention of ARI in primary care settings. Additional observational studies will be embedded and use the infrastructure developed in POS-ARI-PC.
Read the detailed description
The main aim for POS-ARI-PC is to provide a platform for continuous data capture for patients with ARI presenting to primary care settings across Europe, covering cases caused by known and emerging respiratory pathogens with epidemic and pandemic potential, in order to generate observational evidence to inform care and maintain study- readiness for RCT evaluations. The POS-ARI-PC platform will thereby support the efficient set-up of new clinical studies and trials, which will be embedded into the platform.
We have developed two overarching protocols for the POS-ARI-PC. The POS-ARI-PC AUDIT protocol allows for a flexible annual anonymous prospective audit-type registration to describe the presentation and management of patients presenting in primary care with ARI. This provides the infrastructure for patient sampling and follow-up, and in which randomisation can be activated for platform trials to evaluate a range of interventions that can be added and replaced over time. This has resulted in the POS-ARI-PC CORE protocol.
POS-ARI-PC AUDIT:
This is a flexible annual anonymous prospective audit-type registration to describe the presentation and management of patients presenting in primary care with ARI. POS-ARI-PC AUDIT will be delivered through a prospective, multi-country, audit-type anonymous registration of presentation and management of approximately 2,000 patients presenting to PC annually across Europe. This audit will benchmark the case mix and care of patients consulting in PC. These can include general practice, urgent care centres, accident and emergency and other acute services in hospitals, for adult and paediatric patients, both in and out of office hours.
POS-ARI-PC CORE:
This is a non-randomised, prospective, observational study of the presentation, management, microbiology and outcome of acute respiratory tract infection in primary care.
POS-ARI-PC CORE has the following three objectives:
Objective 1. A prospective, observational study of ARI patients in primary care to undergo study-specific sampling upon inclusion and be followed up for 28 days to capture the aetiology of their ARI and describe clinical outcomes.
Objective 2. A qualitative study with research professionals, clinicians, and patients to a) gain a deep understanding of the research process, and the meaning of results and to identify barriers and opportunities for implementation of changes considering findings, and b) explore the views and experiences of patients who consult European primary care services for ARI symptoms since the COVID-19 pandemic.
Objectives 3. To ensure research readiness for including embedded observational and randomised evaluations to answer questions about the effectiveness of diagnostic, behavioural or therapeutic management strategies for ARI in PC. When a new embedded observational study or RCT is added to the POS-ARI-PC a study-specific appendix (SSA) or an intervention-specific appendix (ISA) will be developed which details the (changes in) the study population, the research question, objectives, outcomes, study-specific processes and analysis. This will be appended to the POS-ARI-PC CORE Protocol and all appropriate approvals will be gained for each SSA or ISA.
Participation in the study will last for 28 days. Once consented to the study, a member of the study team will complete a short questionnaire collecting the participants' names and contact information, some details about them, and the symptoms they have been experiencing. A combined throat/nose swab will be collected from the patient for study purposes.
Participants will also be asked to tell us about how they are feeling today and for the next 14 days via an online or paper daily diary. They might be telephoned to ask some questions if they are unable to complete the daily diary. Their GP will be contacted after day 28 to collect information about their consultations and hospital referrals in the 28-day period.
A small number of enrolled participants who consented (optional) to be contacted by the research team about the nested qualitative study will be invited for a process evaluation interview.
POS-ARI-PC-001:
The first embedded study, POS-ARI-PC-001, will be conducted as a prospective observational study to estimate the incidence of medically-attended RSV, HMPV, HPIV and RV infections in an elderly population. This embedded study is appended to the POS-ARI-PC CORE Protocol as a study specific appendix (SSA).
- Conditions
- Acute Respiratory Tract Infection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| POS-ARI-PC | POS-ARI-PC AUDIT: Anonymous registration of patients of any age presenting at the participating primary care facility with ARI. POS-ARI-PC CORE: Patients of any age presenting at the participating primary care facility with ARI. POS-ARI-PC-001: Patients 60 and over, or aged 50 to 59 years and have a long-term health condition which makes them eligible for the yearly influenza vaccination under the national influenza vaccination programme, presenting at the participating primary care facility with ARI. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Age Bands
Participant age recorded at baseline by site study team.
Measured: Baseline (Day 0)
The proportion with a preliminary diagnosis of various sub-categories of ARI (e.g. LRTI, URTI)
Working diagnosis recorded at baseline by site study team.
Measured: Baseline (Day 0)
Overall illness severity rating
Overall illness severity (clinician's impression) recorded at baseline (mild, moderate or severe) by site study team.
Measured: Baseline (Day 0)
Swab samples taken and retrospective viral/microbiological infection analysis performed (multiplex PCR) to identify potential causative pathogens.
Participants have a combined oropharyngeal and nasal swab taken at the baseline visit which will be subjected to PCR-based analysis to identify potential causative pathogens.
Measured: Baseline (Day 0)
Proportion undergoing POC (with results) and lab-based investigations
POC investigations recorded at baseline and results recorded at day 28 by site study team.
Measured: Baseline (Day 0) and day 28.
Details of prescriptions given on presentation of ARI
Prescriptions given at presentation recorded at Baseline by site study team.
Measured: Baseline (Day 0)
Details of tests ordered on presentation of ARI
Tests ordered at presentation recorded at Baseline by site study team.
Measured: Baseline (Day 0)
Return to usual daily activities
Participants asked if they have returned to usual activities in daily diary.
Measured: Day 1-14
Feeling recovered from RTI
Participants asked if they are feeling recovered from RTI in daily diary.
Measured: Day 1-14
Use of prescription medication
Participants asked if they have used prescription medication for the RTI in daily diary.
Measured: Day 1-14
Use of over the counter medications
Participants asked if they have used over the counter medication for the RTI in daily diary.
Measured: Day 1-14
Complications reported associated to ARI presentation
Recorded at day 28 by a member of the site study team.
Measured: Day 28
Variation in practice and advice from national guidelines, to be fed back to national teams
Practice and advise recorded at Baseline by site study team.
Measured: Baseline (Day 0)
Secondary outcomes (4)
Recommendations on how to improve study processes, recruitment and study communication based on shared understanding and insights from researchers, clinicians, and patients.
Using qualitative research methods, interviews conducted with research professionals, clinicians and patients to gain a deep understanding of the research process, meaning of results and to identify barriers and opportunities for implementation of findings. Capturing patients' views on their vulnerability towards ARI in the community since the COVID19 pandemic.
Measured: After day 28
An understanding of the meaning of study results for European primary care, from the perspectives of clinicians and patients, and recommendations regarding the implementation of findings.
Using qualitative research methods, interviews conducted with research professionals, clinicians and patients to gain a deep understanding of the research process, meaning of results and to identify barriers and opportunities for implementation of findings. Capturing patients' views on their vulnerability towards ARI in the community since the COVID19 pandemic.
Measured: After day 28
An understanding of changing health-seeking behaviour, management and expectations to inform clinical studies and trials
Measured using an interview conducted by the social science team after taking part in the main study and using a descriptive analysis
Measured: After day 28
Approval for a study-specific appendix (SSA) or an intervention-specific appendix (ISA) of an embedded (non) randomised study for ARI in primary care associated with this POS, measured using the number of embedded studies to this POS-ARI-PC platform over
To ensure research readiness for including embedded observational and randomised evaluations to answer questions about the effectiveness of diagnostic, behavioural or therapeutic management strategies for ARI in PC.
Measured: Through study completion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2024
- Study start22 Feb 2024
- Primary completion31 May 2027 (estimated)
- Study completion30 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Respiratory Tract InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- European Clinical Research Alliance for Infectious Diseases (ECRAID)
- Sponsor type
- University, hospital or other
- Collaborators
- UMC Utrecht, University of Oxford, Universiteit Antwerpen
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06282718
- Sponsor's protocol ID
- POS-ARI-PC CORE and AUDIT
- Other IDs
- 965313, 10204126, 55487, 324504
- Acronym
- POS-ARI-PC
- Status last verified
- Sep 2026
- First submitted
- 31 Jan 2024
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perpetual Observational Study (POS) of Acute Respiratory Infections (ARI) in Primary Care Settings (PC) Across Europe
- ClinicalTrials.gov ID
- NCT06282718
- Acronym / sponsor ID
- POS-ARI-PC / POS-ARI-PC CORE and AUDIT
- Conditions
- Acute Respiratory Tract Infection
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- European Clinical Research Alliance for Infectious Diseases (ECRAID)University, hospital or other
- Collaborators
- UMC Utrecht, University of Oxford, Universiteit Antwerpen
- Study start
- 22 Feb 2024 (actual)
- Primary completion
- 31 May 2027 (estimated)
- Study completion
- 30 Aug 2027 (estimated)
- First posted
- 28 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute respiratory infection (ARI) is the commonest reason for consulting in community care. Furthermore, new and re-emerging pathogens are often first noticed in primary care (PC). The POS-ARI-PC study is a long-term study, with the aim of describing the nature of ARI in adults and children presenting to PC across Europe. The POS-ARI-PC study will provide critically important data on the presentation and management of ARI, and build a research-ready infrastructure for studies related to the treatment, diagnosis, and prevention of ARI in primary care settings. Additional observational studies will be embedded and use the infrastructure developed in POS-ARI-PC.
Detailed description
The main aim for POS-ARI-PC is to provide a platform for continuous data capture for patients with ARI presenting to primary care settings across Europe, covering cases caused by known and emerging respiratory pathogens with epidemic and pandemic potential, in order to generate observational evidence to inform care and maintain study- readiness for RCT evaluations. The POS-ARI-PC platform will thereby support the efficient set-up of new clinical studies and trials, which will be embedded into the platform.
We have developed two overarching protocols for the POS-ARI-PC. The POS-ARI-PC AUDIT protocol allows for a flexible annual anonymous prospective audit-type registration to describe the presentation and management of patients presenting in primary care with ARI. This provides the infrastructure for patient sampling and follow-up, and in which randomisation can be activated for platform trials to evaluate a range of interventions that can be added and replaced over time. This has resulted in the POS-ARI-PC CORE protocol.
POS-ARI-PC AUDIT:
This is a flexible annual anonymous prospective audit-type registration to describe the presentation and management of patients presenting in primary care with ARI. POS-ARI-PC AUDIT will be delivered through a prospective, multi-country, audit-type anonymous registration of presentation and management of approximately 2,000 patients presenting to PC annually across Europe. This audit will benchmark the case mix and care of patients consulting in PC. These can include general practice, urgent care centres, accident and emergency and other acute services in hospitals, for adult and paediatric patients, both in and out of office hours.
POS-ARI-PC CORE:
This is a non-randomised, prospective, observational study of the presentation, management, microbiology and outcome of acute respiratory tract infection in primary care.
POS-ARI-PC CORE has the following three objectives:
Objective 1. A prospective, observational study of ARI patients in primary care to undergo study-specific sampling upon inclusion and be followed up for 28 days to capture the aetiology of their ARI and describe clinical outcomes.
Objective 2. A qualitative study with research professionals, clinicians, and patients to a) gain a deep understanding of the research process, and the meaning of results and to identify barriers and opportunities for implementation of changes considering findings, and b) explore the views and experiences of patients who consult European primary care services for ARI symptoms since the COVID-19 pandemic.
Objectives 3. To ensure research readiness for including embedded observational and randomised evaluations to answer questions about the effectiveness of diagnostic, behavioural or therapeutic management strategies for ARI in PC. When a new embedded observational study or RCT is added to the POS-ARI-PC a study-specific appendix (SSA) or an intervention-specific appendix (ISA) will be developed which details the (changes in) the study population, the research question, objectives, outcomes, study-specific processes and analysis. This will be appended to the POS-ARI-PC CORE Protocol and all appropriate approvals will be gained for each SSA or ISA.
Participation in the study will last for 28 days. Once consented to the study, a member of the study team will complete a short questionnaire collecting the participants' names and contact information, some details about them, and the symptoms they have been experiencing. A combined throat/nose swab will be collected from the patient for study purposes.
Participants will also be asked to tell us about how they are feeling today and for the next 14 days via an online or paper daily diary. They might be telephoned to ask some questions if they are unable to complete the daily diary. Their GP will be contacted after day 28 to collect information about their consultations and hospital referrals in the 28-day period.
A small number of enrolled participants who consented (optional) to be contacted by the research team about the nested qualitative study will be invited for a process evaluation interview.
POS-ARI-PC-001:
The first embedded study, POS-ARI-PC-001, will be conducted as a prospective observational study to estimate the incidence of medically-attended RSV, HMPV, HPIV and RV infections in an elderly population. This embedded study is appended to the POS-ARI-PC CORE Protocol as a study specific appendix (SSA).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| POS-ARI-PC | – | –POS-ARI-PC AUDIT: Anonymous registration of patients of any age presenting at the participating primary care facility with ARI. POS-ARI-PC CORE: Patients of any age presenting at the participating primary care facility with ARI. POS-ARI-PC-001: Patients 60 and over, or aged 50 to 59 years and have a long-term health condition which makes them eligible for the yearly influenza vaccination under the national influenza vaccination programme, presenting at the participating primary care facility with ARI. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients of any age group presenting to primary care settings with an ARI.
Key inclusion criteria (9 listed)
- Eligible patients will be of any age consulting (telephone, video, face-to-face) with a participating health care facility with:
- Symptoms suggestive of an acute lower RTI with cough as predominant symptom and with illness duration less than 28 days, AND/OR
- Symptoms suggestive of an acute upper RTI with sore throat and/or coryza as predominant symptom and with illness duration of less than 14 days AND/OR
- Patients otherwise suspected of COVID-19, influenza or RSV.
- Eligible patients will be of any age consulting (telephone, video, face to face) with a participating primary health care facility with:
Key exclusion criteria (12 listed)
- Patients will not be eligible for if they have withdrawn their consent for anonymous data collection for research by their health care facility.
- According to the judgement of the recruiting clinician, they will not be able comply with study procedures, for example because they do not understand the language in which the study is being conducted locally (and have no one to help and translate for them); have a serious psychiatric disorder; or are terminally ill
- Symptoms of presumed non-infective origin
- Participant requires admission to hospital on the day of inclusion
- Additional in/exclusion criteria might apply to embedded studies and will be described in the SSA or ISA.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Age Bands
Time frame: Baseline (Day 0)
Participant age recorded at baseline by site study team.
The proportion with a preliminary diagnosis of various sub-categories of ARI (e.g. LRTI, URTI)
Time frame: Baseline (Day 0)
Working diagnosis recorded at baseline by site study team.
Overall illness severity rating
Time frame: Baseline (Day 0)
Overall illness severity (clinician's impression) recorded at baseline (mild, moderate or severe) by site study team.
Swab samples taken and retrospective viral/microbiological infection analysis performed (multiplex PCR) to identify potential causative pathogens.
Time frame: Baseline (Day 0)
Participants have a combined oropharyngeal and nasal swab taken at the baseline visit which will be subjected to PCR-based analysis to identify potential causative pathogens.
Proportion undergoing POC (with results) and lab-based investigations
Time frame: Baseline (Day 0) and day 28.
POC investigations recorded at baseline and results recorded at day 28 by site study team.
Details of prescriptions given on presentation of ARI
Time frame: Baseline (Day 0)
Prescriptions given at presentation recorded at Baseline by site study team.
Details of tests ordered on presentation of ARI
Time frame: Baseline (Day 0)
Tests ordered at presentation recorded at Baseline by site study team.
Return to usual daily activities
Time frame: Day 1-14
Participants asked if they have returned to usual activities in daily diary.
Feeling recovered from RTI
Time frame: Day 1-14
Participants asked if they are feeling recovered from RTI in daily diary.
Use of prescription medication
Time frame: Day 1-14
Participants asked if they have used prescription medication for the RTI in daily diary.
Use of over the counter medications
Time frame: Day 1-14
Participants asked if they have used over the counter medication for the RTI in daily diary.
Complications reported associated to ARI presentation
Time frame: Day 28
Recorded at day 28 by a member of the site study team.
Variation in practice and advice from national guidelines, to be fed back to national teams
Time frame: Baseline (Day 0)
Practice and advise recorded at Baseline by site study team.
4 secondary outcomes
Recommendations on how to improve study processes, recruitment and study communication based on shared understanding and insights from researchers, clinicians, and patients.
Time frame: After day 28
An understanding of the meaning of study results for European primary care, from the perspectives of clinicians and patients, and recommendations regarding the implementation of findings.
Time frame: After day 28
An understanding of changing health-seeking behaviour, management and expectations to inform clinical studies and trials
Time frame: After day 28
Approval for a study-specific appendix (SSA) or an intervention-specific appendix (ISA) of an embedded (non) randomised study for ARI in primary care associated with this POS, measured using the number of embedded studies to this POS-ARI-PC platform over
Time frame: Through study completion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Respiratory Tract Infection
Not yet recruiting
Multimodal Stewardship Programme to Improve Antibiotic Prescribing for Children With Lower Respiratory Tract Infections
Bronchitis, Acute, Community-acquired Pneumonia
Recruiting
Artificial Intelligence Diagnostic Decision Support to Reduce Antimicrobial Prescriptions in Young Children With Colds
Acute Otitis Media (AOM), Upper Respiratory Infection
Not yet recruiting
Automatic Versus As-Needed Follow-up After Hospitalization for Children With Medical Complexity
Children With Medical Complexity, Respiratory Tract Infections (RTI)
RecruitingPhase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Viral Lung Infection and Acute Respiratory Failure
Active, not recruitingPhase 2
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nguyen Tran contact
3 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Respiratory Tract Infection, run by European Clinical Research Alliance for Infectious Diseases (ECRAID) at 3 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Belgium, France, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christopher Butler (+44 (0)1865 289670, christopher.butler@phc.ox.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Age Bands (time frame: Baseline (Day 0)). The study lists 13 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026; AzTrials last refreshed its copy on 26 Oct 2026.